文献速递膀胱癌与上尿路尿路上皮癌

多参数磁共振序列辅助肌层浸润性膀胱癌决策的价值

The Value of Multiparametric Magnetic Resonance Imaging Sequences to Assist in the Decision Making of Muscle-invasive Bladder Cancer.
PubMed 文献 · Eur Urol Oncol · 2020-06-27

基于PURE-01研究最终人群,评估多参数磁共振成像(mpMRI)各序列及其组合与肌层浸润性膀胱癌(MIBC)患者接受帕博利珠单抗新辅助治疗后病理缓解的关联。143例入组,123例有配对影像分析(共246次mpMRI)。所有序列组合预测ypT0ypN0的AUC为0.74,排除DCE后AUC仍为0.74;预测ypT1/a/is ypN0的AUC均为0.87。结论支持mpMRI可靠性,并提示可避免钆对比剂以个体化膀胱保留策略。

要点

  • mpMRI组合序列预测ypT0ypN0的AUC为0.74,排除DCE后不变。
  • 预测ypT1/a/is ypN0的AUC为0.87,排除DCE后亦为0.87。
  • 无DCE时,无疾病证据患者中95%为ypT1/a/is ypN0,65%为ypT0ypN0缓解者。

核心结论

  • 最终结果证实mpMRI预测MIBC新辅助帕博利珠单抗后病理缓解的可靠性。
  • 提示可避免静脉钆对比剂,以个体化放射学完全缓解者的膀胱保留策略。

研究设计与样本

  • 基于PURE-01研究最终人群的影像学分析,评估mpMRI序列与病理缓解的关联。
  • 2017年2月至2019年12月入组143例,123例有帕博利珠单抗前后配对影像(共246次mpMRI)纳入分析。

主要发现

  • 所有序列组合预测ypT0ypN0的AUC为0.74,排除DCE后AUC为0.74。
  • 预测ypT1/a/is ypN0的AUC在包含与排除DCE时均为0.87。
  • 无DCE时,无疾病证据患者中95%为ypT1/a/is ypN0,65%为ypT0ypN0缓解者。

临床怎么用

  • mpMRI可用于MIBC新辅助免疫治疗后病理缓解的无创评估。
  • 放射学完全缓解者或可避免静脉钆对比剂,辅助膀胱保留决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Interim data from the PURE-01 study, using pembrolizumab before radical cystectomy in muscle-invasive bladder cancer (MIBC), suggested that multiparametric magnetic resonance imaging (mpMRI) was able to predict the pathologic response. Owing to the availability of novel effective therapies in MIBC, the possibility to assess tumor response easily has become exceedingly important. The primary objective of the present study was to evaluate the association between individual and combined MRI sequences, and the pathologic response in the final PURE-01 population. Images were internally evaluated and the diagnostic performance was analyzed for separate sequences, along with their combination. From February 2017 to December 2019, 143 patients were enrolled in PURE-01, and 123 with suitable paired imaging assessments before and after pembrolizumab tests (N = 246 mpMRI in total) were analyzed in relation to the pathologic response. The area under the curve (AUC) of the combination of all sequences to predict ypT0ypN0 response was 0.74. By excluding dynamic contrast enhancement (DCE) assessment, the AUC was 0.74. When looking at ypT1/a/is ypN0 response, the AUC was 0.87 in both cases. Without DCE, 95% of patients with no evidence of disease resulted in ypT1/a/is ypN0 and 65% ypT0ypN0 responders. In conclusion, the final results confirmed the reliability of mpMRI and suggested the opportunity to avoid intravenous gadolinium contrast to personalize bladder-sparing strategies in radiologically complete responders. PATIENT SUMMARY: We evaluated the reliability of multiparametric bladder magnetic resonance imaging to predict the pathologic response to pembrolizumab administered before radical cystectomy in muscle-invasive bladder cancer. We observed that this radiologic examination is promising in the attempt to identify opportunities to spare the bladder in selected, radiologically defined complete responders. We also observed that the use of intravenous gadolinium contrast can be avoided in future studies. ClinicalTrials.gov, number NCT02736266.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Bandini M, Calareso G, Raggi D, et al. The Value of Multiparametric Magnetic Resonance Imaging Sequences to Assist in the Decision Making of Muscle-invasive Bladder Cancer. Eur Urol Oncol. 2020. PMID: 32605888. doi:10.1016/j.euo.2020.06.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。